CO2020013545A2 - Formulación estable de anticuerpos - Google Patents

Formulación estable de anticuerpos

Info

Publication number
CO2020013545A2
CO2020013545A2 CONC2020/0013545A CO2020013545A CO2020013545A2 CO 2020013545 A2 CO2020013545 A2 CO 2020013545A2 CO 2020013545 A CO2020013545 A CO 2020013545A CO 2020013545 A2 CO2020013545 A2 CO 2020013545A2
Authority
CO
Colombia
Prior art keywords
antibody formulation
stable antibody
formulation
antibody
formulations
Prior art date
Application number
CONC2020/0013545A
Other languages
English (en)
Spanish (es)
Inventor
Murali Jayaraman
Anuja Chandrasekar
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68164052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2020013545(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of CO2020013545A2 publication Critical patent/CO2020013545A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CONC2020/0013545A 2018-04-10 2020-10-28 Formulación estable de anticuerpos CO2020013545A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841013645 2018-04-10
PCT/IN2019/050291 WO2019198099A1 (en) 2018-04-10 2019-04-10 Stable antibody formulation

Publications (1)

Publication Number Publication Date
CO2020013545A2 true CO2020013545A2 (es) 2021-01-18

Family

ID=68164052

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0013545A CO2020013545A2 (es) 2018-04-10 2020-10-28 Formulación estable de anticuerpos

Country Status (10)

Country Link
US (1) US12024561B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773695A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021521168A (cg-RX-API-DMAC7.html)
CN (1) CN112243379A (cg-RX-API-DMAC7.html)
AU (1) AU2019251452A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020020741A2 (cg-RX-API-DMAC7.html)
CO (1) CO2020013545A2 (cg-RX-API-DMAC7.html)
SG (1) SG11202009872YA (cg-RX-API-DMAC7.html)
WO (1) WO2019198099A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006262B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103040732B (zh) * 2003-02-10 2015-04-01 伊兰药品公司 免疫球蛋白制剂及其制备方法
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
PE20120359A1 (es) * 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN112292146A (zh) * 2018-04-10 2021-01-29 雷迪博士实验室有限公司 治疗性抗体的稳定的制剂
SG11202009874QA (en) * 2018-04-10 2020-11-27 Dr Reddys Laboratories Ltd Antibody formulation
AR119268A1 (es) * 2019-06-10 2021-12-09 Millennium Pharm Inc Métodos de purificación de anticuerpos y composiciones de estos
CA3143167A1 (en) * 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Methods of producing an anti-.alpha.4.beta.7 antibody

Also Published As

Publication number Publication date
WO2019198099A1 (en) 2019-10-17
EP3773695A1 (en) 2021-02-17
JP2021521168A (ja) 2021-08-26
AU2019251452A2 (en) 2020-12-03
EP3773695A4 (en) 2021-12-22
SG11202009872YA (en) 2020-11-27
CN112243379A (zh) 2021-01-19
ZA202006262B (en) 2023-01-25
BR112020020741A2 (pt) 2021-01-19
US12024561B2 (en) 2024-07-02
AU2019251452A1 (en) 2020-11-26
US20210253714A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
CO2020013571A2 (es) Formulaciones estables de anticuerpos terapéuticos
CO2019011021A2 (es) Formulacion estable de anticuerpos
CL2020002012A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)
MX2025010757A (es) Formulacion farmaceutica de ph bajo
MX385109B (es) Formulaciones de anticuerpos.
CO2020016008A2 (es) Formulación de proteína de fusión estable
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
MX2015015152A (es) Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13.
BR112016026811A2 (pt) formulação de anticorpo
CL2017001115A1 (es) Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf.
MX2020005561A (es) Proteinas modificadas de union a adn.
CO2022005737A2 (es) Formulación estable de anticuerpo de integrina
CR20190400A (es) Formulaciones de anticuerpo monoclonal anti-vrs
CO2021010697A2 (es) Formulación de anticuerpos terapéuticos
AR095396A1 (es) Formulaciones de anticuerpo
WO2018075692A3 (en) Antibody constructs
AR108631A1 (es) Formulación de neurotoxinas
CO2020016014A2 (es) Formulación de proteína de fusión ctla4-ig
MX380569B (es) Métodos y formulaciones que permiten la modulación de respuestas inmunitarias relacionadas con la administración de un fármaco biofarmacéutico.
MX2021005910A (es) Formulacion de proteina de alta concentracion.
UY38153A (es) Formulaciones acuosas estables de anticuerpos anti-tau
AR117607A1 (es) Formulaciones de anticuerpo líquidas de alta concentración
BR112018011590A2 (pt) formulação cosmética
AR106510A1 (es) Formulaciones de anticuerpo antifactor d
EA202191990A1 (ru) Состав терапевтического антитела